Rocket Pharmaceuticals has repositioned itself around a leaner portfolio targeting rare genetic cardiomyopathies through gene therapies using AAV and lentiviral platforms, leveraging its proprietary US-based cGMP manufacturing. Its past years reflect deepening operating losses though recent cost-cutting has begun to moderate the pace of losses. The company faces ongoing regulatory, clinical, and legal uncertainties, including securities litigation tied to its Danon disease program. Near-term prospects hinge on successful late-stage data readouts and FDA decisions, notably with KRESLADI’s pending PDUFA date in March 2026.